Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An excitatory role for peripheral EP3 receptors in bladder afferent function.
Su X, Lashinger ES, Leon LA, Hoffman BE, Hieble JP, Gardner SD, Fries HE, Edwards RM, Li J, Laping NJ. Su X, et al. Among authors: edwards rm. Am J Physiol Renal Physiol. 2008 Aug;295(2):F585-94. doi: 10.1152/ajprenal.90273.2008. Epub 2008 Jun 18. Am J Physiol Renal Physiol. 2008. PMID: 18562635 Free article.
Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists.
Jin J, Morales-Ramos A, Eidam P, Mecom J, Li Y, Brooks C, Hilfiker M, Zhang D, Wang N, Shi D, Tseng PS, Wheless K, Budzik B, Evans K, Jaworski JP, Jugus J, Leon L, Wu C, Pullen M, Karamshi B, Rao P, Ward E, Laping N, Evans C, Leach C, Holt D, Su X, Morrow D, Fries H, Thorneloe K, Edwards R. Jin J, et al. ACS Med Chem Lett. 2010 May 14;1(7):316-20. doi: 10.1021/ml100077x. eCollection 2010 Oct 14. ACS Med Chem Lett. 2010. PMID: 24900213 Free PMC article.
Structure-activity relationship studies of novel 3-oxazolidinedione-6-naphthyl-2-pyridinones as potent and orally bioavailable EP3 receptor antagonists.
Morales-Ramos ÁI, Li YH, Hilfiker M, Mecom JS, Eidam P, Shi D, Tseng PS, Brooks C, Zhang D, Wang N, Jaworski JP, Morrow D, Fries H, Edwards R, Jin J. Morales-Ramos ÁI, et al. Bioorg Med Chem Lett. 2011 May 15;21(10):2806-11. doi: 10.1016/j.bmcl.2011.03.107. Epub 2011 Apr 5. Bioorg Med Chem Lett. 2011. PMID: 21514150
The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
Abrahamsen CT, Barone FC, Campbell WG Jr, Nelson AH, Contino LC, Pullen MA, Grygielko ET, Edwards RM, Laping NJ, Brooks DP. Abrahamsen CT, et al. Among authors: edwards rm. J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. J Pharmacol Exp Ther. 2002. PMID: 11907153
Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists.
Hilfiker MA, Wang N, Hou X, Du Z, Pullen MA, Nord M, Nagilla R, Fries HE, Wu CW, Sulpizio AC, Jaworski JP, Morrow D, Edwards RM, Jin J. Hilfiker MA, et al. Among authors: edwards rm. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4292-5. doi: 10.1016/j.bmcl.2009.05.074. Epub 2009 May 27. Bioorg Med Chem Lett. 2009. PMID: 19487124
207 results